MEDIDATA, BOEHRINGER INGELHEIM RENEW FIVE-YEAR COLLABORATION

KUALA LUMPUR, Oct 28 (Bernama) -- Medidata, a Dassault Systèmes company, and Boehringer Ingelheim announced a five-year renewal of their collaboration in the wider area of electronic data capture (EDC).

The new agreement extends the use of Rave EDC for Boehringer Ingelheim’s clinical trials worldwide and includes myMedidata, Medidata’s suite of innovative patient-facing technologies focused on enhancing patient centricity and diversity in decentralised clinical trials (DCTs).

“Boehringer Ingelheim’s global reach across therapeutic areas is a perfect match for the scalable capabilities of myMedidata and the rest of the Medidata Clinical Cloud platform. 

“Together, we will be able to quickly improve access and diversity of participation in a wide range of clinical programmes,” said chief executive officer Patient Cloud at Medidata, Anthony Costello in a statement. 

The agreement adds to Boehringer’s focus on engaging patients in a meaningful way by providing Medidata’s scalable patient-centered capabilities. 

This includes the myMedidata patient portal, a single-destination web-based platform, which provides access to electronic consent, electronic Clinical Outcome Assessment (eCOA), and myMedidata LIVE video investigator/patient visits.

Boehringer Ingelheim has built on Medidata technologies including Rave EDC, Coder, targeted source data verification (TSDV) and Safety Gateway. 

Headquartered in New York City, Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies and academic researchers accelerate value, minimise risk and optimise outcomes.

-- BERNAMA